Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jack

Showing results (521-530 of 594) with videos related to

Pageof 60
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)|December 12, 2018
AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public HealthScott M Lippman, Cory Abate-Shen, Karen L Colbert Maresso, et al.
Science (New York, N.Y.)|October 11, 2014
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencingJianjun Zhang, Junya Fujimoto, Jianhua Zhang, et al.
Oncotarget|October 20, 2018
Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of <i>RICTOR/KRAS</i>-altered non-small cell lung cancerDennis Ruder, Vassiliki Papadimitrakopoulou, Kazuhiko Shien, et al.
Medrxiv : the Preprint Server for Health Sciences|March 17, 2025
KRAS <sup>G12D</sup> -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC PatientsValerie S LeBleu, Brandon G Smaglo, Krishnan K Mahadevan, et al.
JAMA Oncology|March 23, 2023
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical TrialDavide Serrano, Sara Gandini, Parjhitham Thomas, et al.
Cancer Immunology, Immunotherapy : CII|March 9, 2021
Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
The Lancet. Oncology|October 30, 2016
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 studyDaniel R Gomez, George R Blumenschein, J Jack Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2021
Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDCBita Sahaf, Mina Pichavant, Brian H Lee, et al.
Cancer Discovery|May 16, 2012
The BATTLE trial: personalizing therapy for lung cancerEdward S Kim, Roy S Herbst, Ignacio I Wistuba, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 18, 2018
A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast DiseaseAyca Gucalp, Xi K Zhou, Elise D Cook, et al.
Pageof 60

Showing results (521-530 of 594) with videos related to

Sort By:
Pageof 60
Cancer Prevention Research (Philadelphia, Pa.)|December 12, 2018
AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public HealthScott M Lippman, Cory Abate-Shen, Karen L Colbert Maresso, et al.
Science (New York, N.Y.)|October 11, 2014
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencingJianjun Zhang, Junya Fujimoto, Jianhua Zhang, et al.
Oncotarget|October 20, 2018
Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of <i>RICTOR/KRAS</i>-altered non-small cell lung cancerDennis Ruder, Vassiliki Papadimitrakopoulou, Kazuhiko Shien, et al.
Medrxiv : the Preprint Server for Health Sciences|March 17, 2025
KRAS <sup>G12D</sup> -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC PatientsValerie S LeBleu, Brandon G Smaglo, Krishnan K Mahadevan, et al.
JAMA Oncology|March 23, 2023
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical TrialDavide Serrano, Sara Gandini, Parjhitham Thomas, et al.
Cancer Immunology, Immunotherapy : CII|March 9, 2021
Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.
The Lancet. Oncology|October 30, 2016
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 studyDaniel R Gomez, George R Blumenschein, J Jack Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2021
Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDCBita Sahaf, Mina Pichavant, Brian H Lee, et al.
Cancer Discovery|May 16, 2012
The BATTLE trial: personalizing therapy for lung cancerEdward S Kim, Roy S Herbst, Ignacio I Wistuba, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 18, 2018
A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast DiseaseAyca Gucalp, Xi K Zhou, Elise D Cook, et al.
Pageof 60